Purvalanol B – 25 mg

Brand:
Cayman
CAS:
212844-54-7
Storage:
-20
UN-No:
Non-Hazardous - /

Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy.{21810} Purvalanol B is a CDK inhibitor that most potently inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively).{6960} It is inactive against Cdk4/cyclin D1 as well as several other protein kinases. Purvalanol B is a 2,6,9-trisubstituted purine that, at micromolar doses, inhibits the growth of parasites, including Plasmodium.{30689,30688}  

 

Available on backorder

SKU: - Category:

Description

A CDK inhibitor that most potently inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdc2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively); inhibits the growth of parasites, including Plasmodium, at micromolar doses


Formal name: 2-chloro-4-[[2-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-9-(1-methylethyl)-9H-purin-6-yl]amino]-benzoic acid

Synonyms:  NG 95

Molecular weight: 432.9

CAS: 212844-54-7

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Antiparasitics|Antiprotozoals||Product Type|Biochemicals|Kinase Inhibitors|CDKs||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cell Biology|Cell Cycle||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Parasitic Diseases